Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

QoL, Efficacy Data Support Use of Frontline Lorlatinib as New Standard in ALK+ NSCLC

February 2nd 2021

February 2, 2021 - The time to treatment deterioration for symptoms such as cough, dyspnea, and pain in the chest was found to be comparable between treatment-naïve patients with ALK-positive non–small cell lung cancer who received lorlatinib versus crizotinib.

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year

February 2nd 2021

February 2, 2021 - ASCO has chosen molecular profiling driving progress in gastointestinal cancers as its Advance of the Year.

Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer

February 1st 2021

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

cfDNA Methylation Assay Allows for Early Lung Cancer Detection

February 1st 2021

February 1, 2021 — Targeted circulating tumor DNA methylation marker panels possess the potential for early blood-based detection of lung cancer with a high sensitivity and specificity.

RET Joins the Ranks of Actionable Targets in Precision Oncology

February 1st 2021

Over the past 2 decades, a growing number of targetable tumor-specific molecular alterations have been identified, ushering in the era of precision oncology. Now, alterations in the RET gene can be added to the list of druggable targets.

HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC

January 30th 2021

January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.

Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

January 30th 2021

January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Amivantamab Shows Encouraging Activity in EGFR Exon 20–Positive NSCLC

January 29th 2021

January 29, 2021 - Amivantamab elicited high and sustained responses in pretreated patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Sotorasib Elicits Rapid Responses, Encouraging PFS in Advanced KRAS G12C+ NSCLC

January 29th 2021

January 28, 2021 - Treatment with the KRAS G12C inhibitor sotorasib (formerly AMG 510) elicited a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non–small cell lung cancer.

NeoADAURA Trial Slated to Examine Neoadjuvant Osimertinib in Resectable EGFR+ NSCLC

January 28th 2021

January 28, 2021 - The NeoADAURA trial will evaluate the safety and efficacy of neoadjuvant osimertinib, as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone, in patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations.

Osimertinib/Savolitinib Combo May Overcome MET Resistance in EGFR+, MET-Amplified NSCLC

January 28th 2021

January 28, 2021 - The combination of osimertinib and savolitinib may be able to overcome MET resistance in patients with EGFR-mutant, MET-amplified or -overexpressed non–small cell lung cancer, including those who have previously progressed on a prior EGFR TKI.

Osimertinib Displays Uniform Brain Penetrance and Reduced Metastatic Volume in EGFR+ NSCLC

January 28th 2021

January 28, 2021 - Rapid, high, and uniform brain exposure was seen with [11C]osimertinib, followed by a reduction in total brain metastases volume with oral administration of the EGFR TKI in patients with EGFR-mutant non–small cell lung cancer and brain metastases.

Real-World Study Confirms NRG1 Fusions in NSCLC, Supports Afatinib Studies

January 28th 2021

January 28, 2021 - NRG1 fusions are detectable in patients with non–small cell lung cancer, providing a rationale to perform larger, retrospective studies assessing therapeutic outcomes in patients with NRG1 fusion–positive tumors and evaluate afatinib in this patient subgroup.

Expert Panel Weighs Practice-Changing Potential of Early Data in EGFR+ NSCLC

January 28th 2021

As new findings emerge in the lung cancer treatment paradigm, innovative strategies have resulted in impressive central nervous system activity and encouraging responses with acceptable tolerability.

Real-World Data Grow Increasingly Relevant in Oncology Practice

January 27th 2021

The importance of objectively valid data is well established in clinical medicine. Such data include an accurate recording of a patient’s clinical history; evaluation of signs and symptoms of illness; and measurement of various routine indicators, such as granulocyte and platelet counts, serum glucose, electrolytes, and liver function tests.

Sabari Stresses the Importance of Molecular Testing in Lung Cancer

January 27th 2021

Joshua K. Sabari, MD, discussed the management of patients with early-stage and metastatic lung cancer, the roles of molecular testing, surgery, staging, and ongoing research efforts in the space.

Durvalumab, Osimertinib Envelop Adjuvant and Neoadjuvant NSCLC Treatment

January 25th 2021

The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.

HER2-Directed Antibody-Drug Conjugates May Carve Out a Place in NSCLC Landscape

January 21st 2021

The current standard of care for patients with non–small cell lung cancer does not include therapies targeting HER2, a mutation that occurs in up to 4% of cases. However, data from recent studies of antibody-drug conjugates directed at HER2 activity are generating excitement about the potential utility of ADCs in this space.

New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward

January 20th 2021

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

Dr. Narla on Advances Made With Precision Medicine in Oncology

January 19th 2021

Goutham Narla, MD, PhD, discusses advances made with precision medicine in oncology.